This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
The antibiotic, marketed as Xacduro, is indicated for hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP) caused by susceptible strains of bacteria called Acinetobacter baumannii.
A Phase III trial has found that the novel combination antibiotic sulbactam-durlobactam prevents at least as many fatalities of hospital-acquired pneumonia as colistin, the best currently approved treatment. However, with these positive trial results, there is potential for the FDA to approve the new antibiotic.
Food and Drug Administration’s oversight of clinical research in hospitals and clinics has fallen considerably in recent years, due to disruptions caused by the Covid pandemic and challenges finding and keeping investigators, according to a new report by the U.S. By comparison, the FDA inspected 976 clinical study sites in 2017.
Lawmakers came close last year to passing a bill that would have given the FDA this authority, but it was ultimately rejected by Republicans who sympathized with the labs in academic medical centers and hospitals that opposed the provision.
recently recalled a slew of injectable medicines used by hospitals over concerns about possible side effects and a newly released regulatory report underscores the extent of the problem. One of the largest compound pharmacy operations in the U.S. facility run by Central Admixture Pharmacy Services.
The group voted 6-0 that an 1,800-patient study of Leqembi confirmed its benefits for patients in the early stages of Alzheimer’s, recommending the FDA widen the drug’s limited approval. The agency, which is not required to follow the suggestions of its advisers, is expected to make a final decision on Leqembi by July 6.
The 12-lead electrocardiogram device, called the Kardia 12L ECG System, is a hand-held version of the standard ECG device usually found in hospitals and used to diagnose heart conditions.
The vaccine, which will be sold under the name Capvaxive, is designed to protect against pneumococcal pneumonia, which hospitalizes about 150,000 adults in the United States every year and kills about 1 in 20 who develop it, according to the National Foundation for Infectious Diseases. Read the rest…
At issue is the Research, Abuse, Diversion, and Addiction-Related Surveillance system, or RADARS, which was originally created as in-house monitoring program by Purdue Pharma and later sold to the Denver Health and Hospital Authority. Continue to STAT+ to read the full story…
The FDA’s decision not to approve Spero Therapeutics’ oral antibiotic tebipenem Hbr for adults with complicated urinary tract infections (cUTI) further increases the threat of antibiotic resistance, according to a GlobalData analyst.
In public, hospitals rave about artificial intelligence. They trumpet the technology in press releases, plaster its use on billboards, and sprinkle AI into speeches touting its ability to detect diseases earlier and make health care faster, better, and cheaper. But on the front lines, the hype is smashing into a starkly different reality.
Developers can’t fully guarantee the algorithm’s performance, explained Califf, because an AI model’s performance evolves over time and performs differently in different hospitals’ patient populations, unlike a drug. And that model drift is “happening in health systems.
It’s mission accomplished for Novartis after the FDA approved ofatumumab for multiple sclerosis, completing a project where the former cancer drug has been repurposed. The FDA approved ofatumumab under the brand name Kesimpta for people living with relapsing forms of multiple sclerosis.
Reviewers from the FDA have given their blessing to the Pfizer/BioNTech COVID-19 vaccine ahead of a key meeting tomorrow – but the regulator noted that there are still uncertainties about whether the shot can stop the disease from spreading. The post FDA reviewers back Pfizer/BioNTech COVID-19 vaccine ahead of panel appeared first on.
A team at the Children’s Hospital of Philadelphia, led by Alan Flake, is the closest to human trials — their device is a bag filled with sterile fluid, which contains the fetus and is connected to tubes providing oxygen and nutrition.
Once FDA regulators decide a device is safe and effective, companies and researchers then attempt to track how the device performs in the real world. This makes it incredibly difficult for researchers to observe device performance trends in claims data, and for hospitals to reach out to patients when specific devices are recalled.
Tara Bannow, our hospitals and insurance reporter, joins us to talk about a new investigation that shows how UnitedHealth wields its unrivaled physician empire to boost its profits and expand its influence. Is Viking Therapeutics an attractive acquisition target? And is Adam good at math?
Intravenous tocilizumab (Actemra; Genentech) has been approved for the treatment of COVID-19 in individuals who are hospitalized and receiving systemic corticosteroids and supplemental oxygen.
Following the FDA approval, the company has created the Reata Education, Access, and Care Helpline ( REACH ), an integrated specialty pharmacy and patient services program, designed to help eligible patients access prescribed Reata medicines.
The panel, whose advice the FDA typically follows, voted that the system developed by ReCor Medical was safe and effective. Luke’s Hospital of Kansas City, said regarding Medtronic’s device. It voted that the benefits of a system developed by Medtronic, however, did not outweigh the risks.
Mount Sinai, a leading hospital network in New York City, has mounted an extraordinary behind-the-scenes campaign to blunt the fallout over revelations about its controversial research project in which brain biopsies are taken from patients undergoing deep brain stimulation, STAT has learned.
Hard on the heels of some impressive clinical trial results, Luminopia has won FDA approval for its digital therapeutic (DTx) for amblyopia or lazy eye in children that is based on watching TV shows. The post Luminopia scores FDA approval for TV-based amblyopia therapy appeared first on. Photo by Jessica Lewis on Unsplash.
The agency has approved the antiviral drug Veklury (remdesivir), produced by Gilead, for hospitalized patients 12 years and over diagnosed with the virus.
I self-referred for GLP-1s years ago after seeing advertisements, and even though I am a diabetic, what followed were horrific health outcomes: hospitalizations, extensive procedures, scans, MRIs, pancreatitis, anemia, and thousands in medical expenses. So I understand why new Health and Human Services Secretary Robert F. Kennedy Jr.
The FDA has granted a priority review to Roche’s T-cell engager Lunsumio as a treatment for follicular lymphoma (FL), setting up a decision on the drug by 29 December. The post FDA to decide on Roche’s lymphoma drug Lunsumio before year-end appeared first on.
Her son, Declan, who turns 2 years old in January, survived a life-threatening episode of cardiac arrest that sent him to a hospital emergency room a year ago. Jamie Dubuque faces the future with a mixture of gratitude and trepidation.
Panelists include leaders from the Food and Drug Administration, the Centers for Disease Control and Prevention, a Harvard Medical School teaching hospital, and electronic health record giant Epic Systems.
The post FDA approves Syfovre for geographic atrophy in advanced age-related macular degeneration appeared first on Hospital Pharmacy Europe. Geographic atrophy (GA) is an advanced form of age-related macular degeneration and which leads to progressive and irreversible loss of vision.
Ohio-based University Hospitals Health System (UH) has teamed up with healthcare AI company Aidoc to catch conditions like pulmonary embolism, coronary artery calcification and intracrani | Aidoc's AI-based image analysis technology will be deployed in University Hospitals.
Critical information, like unique device identifiers that help hospitals keep track of implants in patients, was often missing. She quickly realized that the software was too old and clunky to identify report patterns that would help the agency shut down a product before hurting patients.
Spero Therapeutics has announced that it has gained US Food and Drug Administration (FDA) clearance for the investigational new drug (IND) application to assess SPR206 in a phase 2 clinical study.
… House Republicans have drafted drug-shortage legislation that differs significantly from the approach Democrats propose to stem shortages of chemotherapies and other critical medicines that hospitals typically use , STAT explains. Republicans as being primarily driven by synthetic opioids including illicit fentanyl.
In the early days of the Covid pandemic, gravely ill patients began to fill America’s hospitals. In a 2021 APC survey, more than 80 pharmacies nationwide reported they had provided compounded versions of those essential drugs to hospitals under the temporary guidance.
Ozempic and Wegovy (and Rybelsus , which is oral semaglutide) are GLP-1 receptor agonists (glucagon-like peptide-1 receptor agonists, commonly referred to as GLP-1s) and are the only FDA-approved drugs that contain the active ingredient semaglutide. Some facilities add B12 to their compounds, in addition to semaglutide.
The Pfizer vaccine has also been tested to protect infants in their first six months of life — the age group at highest risk of being hospitalized with RSV — and is expected to gain FDA approval for that population later this year. Continue to STAT+ to read the full story…
WASHINGTON — Medicare has a new proposal to pay hospitals more to stockpile essential drugs — an idea that comes as doctors report running low on critical chemotherapies and other drugs. But Medicare has its own new idea: paying hospitals to create a “buffer stock” of 86 medicines that HHS deems critical.
Ideally, he said, the FDA should be able to both stay on top of safety concerns and avoid unnecessarily restricting access to drugs. I think there are definitely situations for many drugs where you can say, no, we’re not really at the right balance, and the FDA should be taking a more aggressive stance in promoting patient safety.
The FDA protects public health by ensuring the efficacy and safety of human and veterinary drugs, including biological products and medical devices. It is critical for the FDA to continue to develop new advances in therapies to aid our communities in order to achieve better lives through better health. Date of Approval: 9/30/2022.
You’re reading the web edition of STAT’s Health Tech newsletter, our guide to how technology is transforming the life sciences. Sign up to get it delivered in your inbox every Tuesday and Thursday.
If LVEF is 40% or less a patient is considered to have heart failure with reduced ejection fraction (HFrEF), sometimes known as systolic heart failure, which is generally diagnosed in hospital. Eko says it will be submitted to the FDA for approval later his year. The study is published in The Lancet Digital Health.
biopharmaceutical companies conducted clinical trials with China’s military organizations, and specifically with medical centers and hospitals affiliated with the People’s Liberation Army’s,” according to an Aug. “For over a decade, it appears that U.S.
A real-world study of digital therapeutic (DTx) for opioid use disorder has found that patient show used it had 46% fewer hospital stays than a control group, saving more than $2,700 over a nine-month period.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content